NO20030252L - Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon - Google Patents

Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon

Info

Publication number
NO20030252L
NO20030252L NO20030252A NO20030252A NO20030252L NO 20030252 L NO20030252 L NO 20030252L NO 20030252 A NO20030252 A NO 20030252A NO 20030252 A NO20030252 A NO 20030252A NO 20030252 L NO20030252 L NO 20030252L
Authority
NO
Norway
Prior art keywords
polypeptides
compounds
diagnosis
treatment
methods
Prior art date
Application number
NO20030252A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030252D0 (no
Inventor
Steven P Fling
Yasir A W Skeiky
Peter Probst
Ajay Bhatia
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/620,412 external-priority patent/US6448234B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20030252D0 publication Critical patent/NO20030252D0/no
Publication of NO20030252L publication Critical patent/NO20030252L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4568—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20030252A 2000-07-20 2003-01-17 Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon NO20030252L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/620,412 US6448234B1 (en) 1998-12-08 2000-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection
US09/841,132 US20020061848A1 (en) 2000-07-20 2001-04-23 Compounds and methods for treatment and diagnosis of chlamydial infection
PCT/US2001/023121 WO2002008267A2 (en) 2000-07-20 2001-07-20 Compounds and methods for treatment and diagnosis of chlamydial infection

Publications (2)

Publication Number Publication Date
NO20030252D0 NO20030252D0 (no) 2003-01-17
NO20030252L true NO20030252L (no) 2003-03-14

Family

ID=27088713

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030252A NO20030252L (no) 2000-07-20 2003-01-17 Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon

Country Status (24)

Country Link
US (9) US20020061848A1 (enExample)
EP (1) EP1307564B1 (enExample)
JP (1) JP2004513622A (enExample)
KR (1) KR20030016423A (enExample)
CN (1) CN100467600C (enExample)
AT (1) ATE373092T1 (enExample)
AU (2) AU2001280702B8 (enExample)
BR (1) BR0112602A (enExample)
CA (1) CA2418282A1 (enExample)
CY (1) CY1107796T1 (enExample)
CZ (1) CZ2003480A3 (enExample)
DE (1) DE60130468T2 (enExample)
DK (1) DK1307564T3 (enExample)
ES (1) ES2294018T3 (enExample)
HU (1) HUP0400477A3 (enExample)
IL (2) IL153904A0 (enExample)
MX (1) MXPA03000564A (enExample)
NO (1) NO20030252L (enExample)
NZ (3) NZ549873A (enExample)
PL (1) PL209107B1 (enExample)
PT (1) PT1307564E (enExample)
RU (2) RU2003104976A (enExample)
WO (1) WO2002008267A2 (enExample)
ZA (1) ZA200300719B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1140998B1 (en) 1998-12-28 2008-01-23 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1163342B1 (en) 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1177301B1 (en) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE384793T1 (de) 1999-09-20 2008-02-15 Aventis Pasteur Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU784193B2 (en) 1999-12-22 2006-02-16 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
US7731980B2 (en) * 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
GB2370838A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
US20050106162A1 (en) * 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
MXPA05013260A (es) * 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
US20080019994A1 (en) * 2003-11-20 2008-01-24 Robert Brunham Immunization Against Chlamydia Infection
CN101184504A (zh) * 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EP1891096A2 (en) * 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
WO2007030879A1 (en) * 2005-09-13 2007-03-22 Diatech Pty Ltd Diagnostic markers and uses therefor
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
EP1970708A1 (de) * 2007-03-07 2008-09-17 Mikrogen Molekularbiologische Entwicklungs-GmbH Biochip und Verfahren zum selektiven Nachweis von Chlamydia trachomatis-Infektionen
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection
US20100260791A1 (en) * 2007-08-03 2010-10-14 President And Fellows Of Harvard Chlamydia antigens
CA2744739A1 (en) * 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
WO2011118496A1 (ja) 2010-03-23 2011-09-29 和光純薬工業株式会社 クラミジア・トラコマティス検出用プライマー及びプローブ、並びにこれを用いたクラミジア・トラコマティスの検出方法
JP2013545448A (ja) * 2010-10-20 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原及びその使用
US20130095487A1 (en) * 2011-10-18 2013-04-18 University Of South Florida Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections
EP2928491B1 (en) * 2012-12-05 2018-11-21 TheVax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
CN113801191B (zh) * 2021-08-18 2022-05-17 南京大学 一种检测衣原体的多肽探针及其应用
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
US4497899A (en) * 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Chlamydia trachomatis antigens
US4497900A (en) 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Neisseria gonorrhoeae antigens
US4497863A (en) * 1984-03-07 1985-02-05 Milliken Research Corporation Laminated weft insertion fabric
EP0192033B1 (en) 1985-01-14 1996-09-25 Chiron Corporation Chlamydia major outer membrane protein
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0348725A3 (en) 1988-06-29 1990-10-24 Miles Inc. Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same
NZ232562A (en) * 1989-02-17 1992-10-28 Coselco Mimotopes Pty Ltd Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
US5166053A (en) * 1990-02-23 1992-11-24 Miles Inc. Specimen adequacy control for chlamydia assays
JP3018553B2 (ja) * 1990-05-08 2000-03-13 日立化成工業株式会社 クラミジア・トラコマティス抗体測定方法及びクラミジア・トラコマティス感染症診断用製剤
US5725863A (en) 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
DE69327599T2 (de) * 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
AU669000B2 (en) 1992-09-18 1996-05-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthetic peptide vaccine for chlamydia trachomatis
US5549978A (en) * 1992-10-30 1996-08-27 Kabushiki Kaisha Toshiba Magnetoresistance effect element
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
EP0784059B1 (en) 1994-09-20 2009-02-11 Hitachi Chemical Co., Ltd. Polynucleotides encoding an antigenic polypeptide of chlamydia pneumoniae
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
GB9626864D0 (en) 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
GB9516293D0 (en) 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
NZ334114A (en) 1996-07-12 2000-06-23 Univ Manitoba DNA immunization against chlamydia infection comprising a major outer membrane protein (MOMP) or a MOMP fragment linked to a promoter sequence
US6464979B1 (en) 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
WO2001023604A2 (en) 1999-09-28 2001-04-05 Infectio Diagnostic (I.D.I.) Inc. Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
JP4249279B2 (ja) 1997-10-22 2009-04-02 デンカ生研株式会社 クラミジア・トラコマティス主要外膜蛋白質及びその製造方法、並びにクラミジア・トラコマティスの抗体測定方法及び抗体測定試薬
ATE352624T1 (de) 1997-11-21 2007-02-15 Serono Genetics Inst Sa Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
ATE480625T1 (de) * 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
EP2228384A1 (en) * 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
BRPI9915545B8 (pt) * 1998-10-16 2021-05-25 Glaxosmithkline Biologicals Sa composição de vacina, processo para preparação da mesma e kit compreendendo dois recipientes.
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) * 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
CN100365120C (zh) * 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1163342B1 (en) 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1177301B1 (en) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
ATE384793T1 (de) 1999-09-20 2008-02-15 Aventis Pasteur Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
JP2003515737A (ja) * 1999-10-14 2003-05-07 ユニバーシティ オブ ユタ リサーチ ファウンデーション 高感度で高スループットの生物学的センサおよび方法のための共鳴式光キャビティ
AU1481001A (en) 1999-11-19 2001-05-30 Michigan State University Recombinant chlamydia vaccine
AU784193B2 (en) 1999-12-22 2006-02-16 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20010048927A1 (en) * 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1278855B1 (en) * 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
US6589361B2 (en) * 2000-06-16 2003-07-08 Applied Materials Inc. Configurable single substrate wet-dry integrated cluster cleaner
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
WO2002008627A1 (de) * 2000-07-20 2002-01-31 Zf Friedrichshafen Ag Elektromagnetisch betätigbare, schleifringlose einflächen-reibungskupplung
US7731980B2 (en) * 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002079244A2 (en) 2001-03-30 2002-10-10 University Of Manitoba Chlamydial protease-like activity factor responsible for degradation of host transcription factor
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20050106162A1 (en) * 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
US7105171B2 (en) * 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
MXPA05013260A (es) * 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
FR2869057B1 (fr) * 2004-04-16 2006-06-02 Piscines Desjoyaux Sa Sa Dispositif pour la realisation d'un haut de chainage d'un escalier
EP2269636A3 (en) 2004-10-25 2011-04-06 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
US8541007B2 (en) * 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
CN101184504A (zh) * 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
EP1891096A2 (en) * 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
EP1976557A2 (en) * 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US20080124338A1 (en) * 2006-09-22 2008-05-29 The Scripps Research Institute Methods for treatment of inflammatory disease and chlamydia infectious disease
EP2068916A1 (en) * 2006-10-04 2009-06-17 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
JP2012505212A (ja) * 2008-10-09 2012-03-01 ボード・オヴ・リージェンツ，ユニヴァーシティ・オヴ・テキサス・システム クラミジア感染および疾患の診断および治療のためのクラミジア抗原に関する方法および組成物
EP2379106A4 (en) * 2008-12-17 2012-06-13 Genocea Biosciences Inc ANTIGENS OF CHLAMYDIAS AND USES THEREOF
RU2011140508A (ru) * 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
WO2011112670A2 (en) * 2010-03-09 2011-09-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease

Also Published As

Publication number Publication date
NO20030252D0 (no) 2003-01-17
US8263089B2 (en) 2012-09-11
CZ2003480A3 (cs) 2003-09-17
US20090035296A1 (en) 2009-02-05
CY1107796T1 (el) 2013-06-19
US20080181918A1 (en) 2008-07-31
US20020061848A1 (en) 2002-05-23
NZ541013A (en) 2007-05-31
RU2003104976A (ru) 2004-07-10
US8052975B2 (en) 2011-11-08
CN100467600C (zh) 2009-03-11
US7462357B2 (en) 2008-12-09
CA2418282A1 (en) 2002-01-31
AU2001280702B8 (en) 2008-02-28
AU2001280702B9 (en) 2002-02-05
HUP0400477A2 (hu) 2004-05-28
US20040234536A1 (en) 2004-11-25
WO2002008267A2 (en) 2002-01-31
MXPA03000564A (es) 2004-12-13
RU2006120003A (ru) 2007-12-27
EP1307564A2 (en) 2003-05-07
AU2001280702B2 (en) 2008-01-24
WO2002008267A9 (en) 2006-09-28
IL153904A0 (en) 2003-07-31
JP2004513622A (ja) 2004-05-13
US20080317772A1 (en) 2008-12-25
IL153904A (en) 2010-04-29
US20110142872A1 (en) 2011-06-16
PL365951A1 (pl) 2005-01-24
EP1307564B1 (en) 2007-09-12
US20090028887A1 (en) 2009-01-29
ATE373092T1 (de) 2007-09-15
KR20030016423A (ko) 2003-02-26
BR0112602A (pt) 2004-02-17
US20120114684A1 (en) 2012-05-10
DE60130468D1 (de) 2007-10-25
NZ549873A (en) 2008-06-30
PT1307564E (pt) 2007-11-21
HUP0400477A3 (en) 2010-01-28
DE60130468T2 (de) 2008-04-03
CN1489628A (zh) 2004-04-14
ZA200300719B (en) 2004-10-27
PL209107B1 (pl) 2011-07-29
HK1067381A1 (zh) 2005-04-08
RU2410394C2 (ru) 2011-01-27
US20080299142A1 (en) 2008-12-04
NZ523628A (en) 2005-08-26
DK1307564T3 (da) 2007-12-27
ES2294018T3 (es) 2008-04-01
AU8070201A (en) 2002-02-05
WO2002008267A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
NO20030252D0 (no) Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon
NZ518917A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001081379A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
NO20012812D0 (no) Forbindelser og fremgangsmåter for behandling og diagnose av chlamydiainfeksjon
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2003041560A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
DE60125537D1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP0834567A3 (en) Compounds and methods for the diagnosis and treatment of Babesia microti infection
WO2003020108A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection
WO2001085947A3 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application